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1. Introduction 
Chronic infections can lead to cancer. However, acute infection has beneficial effects often 
contributing to complete eradication of tumors. In the wake of this, bacteria and their related 
products were applied therapeutically for experimental immunotherapy. They exhibit direct 
antitumoral potential and are recognized by the host’s immune system via Toll-like 
receptors (TLRs) finally promoting pro-inflammatory, often Th1-directed immune 
responses.  
Recently, we described that local injection of live as well as lysed gram-positive Group A 
Streptococci (GAS) eradicates established pancreatic tumors in mice (Linnebacher et al., 
2008; Maletzki et al., 2008). This antitumoral effect could be attributed to activation of 
immune response mechanisms including both the innate and even more important, the 
adaptive arm of the immune system. In the face of the vigorous immune attack induced by 
S. pyogenes, the identification of factors responsible for tumor disintegration might provide 
the basis for development of therapeutic approaches. Amongst other virulence factors 
delivered by S. pyogenes, the cytolysins Streptolysin O (SLO) and S (SLS) represent the most 
obvious therapeutically active candidates (Fraser & Proft, 2008; Hobohm et al., 2008; Nizet et 
al., 2008). SLO is an oxygen-labile, pore-forming toxin mediating cytolysis by disturbing the 
balance between influxes and effluxes across the cell membrane. While SLS is non-
immunogenic in the natural course of infection and can clinically be identified by beta-
haemolysis surrounding GAS colonies grown on blood agar. Besides their capacity to lyse 
erythrocytes, SLS also exerts cytolytic effects towards tumor cells and is by weight one of the 
most potent cytotoxins known (Ginsberg, 1999; Taketo & Taketo, 1966). 
To address the question of the SLS contribution  to the antitumoral effects observed in our 
previous studies, we performed a series of in vivo experiments in our murine syngeneic 
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Panc02 tumor model using different strategies of SLS-inactivation. Endpoints of the study 
were survival and tumor response. In a first series of experiments, a vital mutant strain, 
unable to produce SLS (ΔsagA) was injected into tumor-carrying mice. This ΔsagA mutant 
has been described to exhibit reduced cytotoxicity. In vitro and in a nude mouse model in 
vivo, effects were induced by minimal inflammation and lesser necrotic skin lesions than the 
isogenic wildtype strain (Datta et al., 2005). However, to circumvent the potential risk of 
unpleasant side effects of live bacteria such as systemic toxicity, another microbial 
preparation of SLS-inactivated bacteria (by heating) was employed. Our in vivo data show 
that local application of SLS-negative agents attenuates the antitumoral effects. Moreover, 
potent immune responses are only marginally induced, most likely because of reduced 
tumor cell impairment after infection, finally leading to an inhibition of vigorous 
antitumoral activity.  
In summary, when comparing with our earlier findings on using S. pyogenes as an active 
immunotherapeutic compound, the present data imply SLS as major antitumoral molecule 
both directly by acting on tumor cells and indirectly by activating the immune system. 
2. Material & methods 
2.1 Cell culture & mice 
All cell lines (Panc02, EL4, CMT-93, and MC3T3-E1) were maintained in DMEM/HamsF12 
supplemented with 10% fetal calf serum (FCS), L-glutamine (2mmol/l) and antibiotics. All 
media and supplements were from PAA unless stated otherwise (Cölbe, Germany). Female 
8–10-week-old C57Bl/6N mice were purchased from Charles River Inc. (Sulzfeld, Germany). 
Animals were exposed to cycles of 12 h light/12 h darkness and received standard food and 
water ad libitum. Upon approval by the local animal welfare committee, experiments were 
performed in accordance with the German legislation on protection of animals and the 
‘‘Guide for the Care and Use of Laboratory Animals’’. 
2.2 Bacteria, toxin and culture conditions 
Bacteria (S. pyogenes serotype M49 strain 591; the ΔsagA mutant isogenic to strain 591 is a 
kind gift from Victor Nizet: A detailed description of how this mutant was generated can be 
found in (Datta et al., 2005)) were cultured in Todd-Hewitt (TH) broth or on TH agar (Oxoid 
Unipath, Wesel, Germany), both supplemented with 0.5 % yeast extract (THY) overnight to 
mid-log phase. Concentration was adjusted on the basis of an optical density reading at 600 
nm and on plating analysis. Heat-inactivation of bacteria was obtained by one-hour 
incubation in a water bath at 75 °C. Inactivation was confirmed by plating samples on sheep 
blood agar followed by over night incubation at 37 °C and 5 % CO2. The purified toxin SLS 
(originally obtained from Sigma Aldrich, Munich, Germany) was dissolved in sterile PBS 
and supplemented with complete cell culture medium before treatment of cells.  
2.3 Hemolysis assay for SLS activity 
Hemolytic activity of SLS was determined by hemoglobin release from whole blood cells 
after 4 and 24 h incubation with bacteria or their related products. Briefly, whole blood of 
healthy donors was seeded in 96-well plates and supplemented with microbia. Following 
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the incubation time, cell-free supernatants were transferred into a new 96-well plate and 
absorption was measured on a plate reader at 340 nm. Hemolytic activity was quantified by 
setting values of untreated cells as 1 and all other data were given as x-fold increase. 
2.4 Cellular cytotoxicity assays 
Toxicity of bacteria towards tumor cells was quantified using a cytotoxicity detection kit 
(Roche, Mannheim, Germany) according to the manufacturer’s instructions. Quantification 
was performed by subsequent measurement on a plate reader at 492 nm.  
For detection of apoptosis, activity of Caspase 3 was analyzed using the BD ApoAlert 
Caspase Assay plate system according to the manufacturer’s instructions (BD Biosciences, 
Heidelberg, Germany). Cells were trypsinized and subsequently lysed. Quantification of 
Caspase 3 activity was performed by fluorometric detection on a Cytofluor 2300 (Millipore, 
Schwalbach, Germany, ex/em: 380/460 nm).  
2.5 Pancreatic tumor model & treatment regimen 
Under brief ether anaesthesia 1*106 Panc02 were injected subcutaneously (s.c.) into the right 
hind leg. Tumor growth was routinely controlled at least twice a week and tumor volume 
was estimated according to the formula: V= width² * length * 0.52. After tumor 
establishment animals were subdivided into experimental groups. All treatments were 
performed by local, intratumoral application of bacterial preparations each dissolved in 
50 µl of phosphate-buffered saline (PBS) according to the following treatment regimen: One 
group was given heat-inactivated S. pyogenes (8 x 107 cfu, four injections once a week, n=6). 
The second group received a single injection of the SLS-mu (ΔsagA). For control, mice were 
administered equivalent volumes of solvent alone (vehicle-treated controls, saline, n=6) or 
left without treatment (control, n=6). Tumor carrying mice (treatment, control) were 
sacrificed at day 28 or when they became moribund before the tumor volume reached 2000 
mm³. At the end of each experiment, tumors as well as spleens, mesenteric lymph nodes, 
and blood samples were removed from selected animals for further analysis. For 
visualization of tumor-infiltrating leukocytes, frozen sections of resected tumor tissues (6 
µm) were stained by the As-D chloroacetate esterase (As-D) technique. Numbers of 
leukocytes/mm² were determined in blinded counts by positive staining and morphology in 
20 consecutive high power fields (HPF). 
2.6 Phenotyping of lymphocyte subpopulations by flow cytometry 
Leukocytes from treated and non-treated animals were labeled using the following FITC-
conjugated rat anti-mouse monoclonal antibodies (mAbs): CD3, CD19, NK1.1 (1 µg, 
Immunotools, Friesoythe, Germany), and Phycoerythrin (PE)-conjugated rat anti-mouse 
mAbs: CD4, CD8 (Miltenyi Biotec, Bergisch Gladbach, Germany). Afterwards, erythrocytes 
were lysed using FACS Lysing Solution (BD Pharmingen, Heidelberg, Germany). Negative 
controls consisted of blood lymphocytes stained with the appropriate isotypes (BD 
Pharmingen). Samples were analyzed on a FACSCalibur Cytometer (BD Biosciences). Data 
analysis was performed using CellQuest software (BD Biosciences) and gating on total 
leukocytes (Mounting View, BD Biosciences). Relative numbers are given. 
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2.7 ELISPOT assay for Interferon-γ–secreting lymphocytes 
IFN-γ–specific, mAb (Mabtech, Hamburg, Germany) –coated, 96-well microtiter plates were 
filled with 1 x 104 target cells/well (Panc02, EL4, CMT-93, MC3T3-E1, and peripheral blood 
mononuclear cells (PBMC)) and incubated for 2 h. Splenocytes (105) were given to the 
targets and co-cultured overnight. Finally, bound antibody was visualized by BCIP/NBT 
(KPL, Gaithersburg, Maryland, USA), and spots were counted using a dissection microscope 
(Zeiss, Oberkochen, Germany). Presented are the numbers of IFN-γ–secreting cells per 105 
effector cells corrected for background levels counted in the absence of target cells, which 
usually was between 10–50 spots/105 cells. Target cells without effector cells showed no 
background level. 
2.8 LDH cytotoxicity assay 
The colorimetric CytoTox-One Homogeneous Membrane Integrity Assay (Promega, 
Madison, WI) was used evaluating lactate dehydrogenase (LDH) release from lysed cells. 
Experiments were performed as described before (Maletzki et al., 2008). 
2.9 Bio-plex protein array system 
A panel of serum cytokines was measured in duplicate using the Bio-Plex Protein Array 
system (BioRad, Munich, Germany), according to the manufacturer’s instructions. With the 
Bio-Plex cytokine assay kit in combination with the Bio-Plex Manager Software, serum IFN-
γ, TNF-α, IL-6, IL-10, GM-CSF (granulocyte macrophage colony stimulating factor), and G-
CSF (granulocyte-colony stimulating factor) levels were assessed. Values of the respective 
serum cytokine levels of untreated control mice were set as 1, and all other data were given 
as x-fold increase. 
2.10 Statistical analysis 
All values are expressed as mean ± SEM. After proving the assumption of normality, 
differences between saline and treated animals were determined by using the unpaired 
Student’s t-test. If normality failed, the nonparametric Mann-Whitney U-Test was applied. 
Similarly, differences between treated and non-treated cell in vitro were calculated by using the 
nonparametric Mann-Whitney U-Test. Data were recruited from experiments which had been 
done in triplicates and replicated at least three times. The tests were performed by using 
Sigma-Stat 3.0 (Jandel Corp, San Rafael, CA). The criterion for significance was set to p < 0.05. 
3. Results 
3.1 In vitro analysis 
First, activity of SLS from different bacterial preparations was analyzed in a simple 
hemoglobin release assay (Figure 1). As expected, the purified toxin mediated substantial 
lysis of erythrocytes within a few hours. In contrast, lysis was completely absent post 
infection with the ΔsagA strain or the heat-inactivated form of the M49wt, thereby 
confirming inactivation of the toxin. As a control, vital M49 bacteria and the lysate, used in 
our previous studies (Maletzki et al., 2008), were employed. Both preparations mediated 
nearly complete lysis of erythrocytes. 
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Fig. 1. Lytic activity of different bacterial preparations towards erythrocytes in whole blood 
samples. Following treatment with increasing concentrations of bacteria, cell-free 
supernatants were harvested and absorption was measured on a plate reader at 340 nm. 
Lytic activity was quantified by setting values of untreated cells as 1, and all other data were 
given as x-fold increase. Results show data from at least three separate experiments each 
performed with two healthy volunteer’s blood samples. Values are given as the mean±SEM. 
In order to elucidate, if SLS also directly damages tumor cells, we applied the purified toxin in 
LDH release experiments. In particular, Panc02 tumor cells were treated with three increasing 
concentrations (25, 50, and 100 U/ml) for six hours. These analyses revealed a dose-dependent 
increase in cell damage with a maximum of up to 65% (100 U/ml). To a minor part, these 
effects could be attributed to the induction of apoptosis as the activity of the effector caspase 3 
slightly increased after treatment with the 100 U/ml doses of SLS (Figure 2).  
In line with these findings, a ΔsagA strain of S. pyogenes mediated no significant growth 
inhibition or killing activity at a multiplicity of infection of 25 for four and six hours (Figure 
2). Also, activity of Caspase 3 was not altered post infection. 
3.2 SLS-deficient preparations of S. pyogenes have minor antitumoral potential 
To further clarify the antitumoral potential of the toxin SLS a series of in vivo experiments 
using two different preparations of inactivated SLS was performed (Figure 3a). Panc02 tumors 
established subcutaneously in C57Bl/6 mice were infected with the ΔsagA strain (107 cfu). The 
intratumoral administration of ΔsagA did not affect pancreatic carcinoma growth within the 
first three weeks. Palpable tumors continued to grow and reached an average size of 723.8 ± 
95.8 mm3, which was comparable to tumor sizes of control animals (saline: 841.4 ± 96.3 mm3). 
Thereafter, tumors in the infection group became frequently ulcerous and necrotized. This 
finally resulted in about 40 % reduced tumor volumes compared to saline-treated animals (day 
28: 689.2 ± 119.8 mm3 vs. saline: 1228.1 ± 220.2 mm3, p < 0.05).  
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Fig. 2. In vitro analysis on direct effects of SLS on tumor cells. (A) Quantitative analysis of 
SLS cytotoxicity towards Panc02 cells as assessed by either LDH release or caspase activity 
following a 6 h incubation period. These analyses revealed a dose-dependent increase in cell 
damage. (B) Quantitative analysis of the ΔsagA effects on Panc02 tumor cells. Infection with 
the ΔsagA strain mediated no significant cytotoxicity, detected by LDH release. Results 
show data from three separate experiments. Values are given as the mean±SEM. *p<0.05 vs. 
control, U-Test. 
To validate these findings, tumor-carrying animals were repeatedly treated with a bacterial 
preparation which was preheated to inactivate SLS. Similar to what has been observed after 
i.t. infection with the ΔsagA strain, injection of heat-inactivated streptococci mediated no 
significant alteration of Panc02 tumor growth until day 14 post start of therapy. However, 
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when comparing to controls, tumors showed a trend towards growth retardation, 
suggesting only reduced but not completely abolished antitumoral potential of the heat-
inactivated bacteria. Hence, the final tumor volume at day 28 was significantly lower than in 
saline-treated mice (693.2 ± 63.0 mm3 vs. 1154.5 ± 277.1 mm3, p < 0.05).  
3.3 Survival  
Animals were sacrificed at day 28 post start of therapy. Infection with the ΔsagA strain was 
well tolerated by most animals, with only one animal displaying signs of systemic bacterial 
infection (i.e. weight loss, ataxia). Because of the severity of infection, this animal was 
euthanized and related data excluded. As expected, the heat-inactivated bacterial 
preparation had no negative impact on survival (Figure 3b).  
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Fig. 3. Data of in vivo analysis of Panc02-tumor carrying C57Bl/6N mice. (A) Tumor growth 
kinetics and (B) survival curve after i.t. application of bacteria. Treatment regimens comprised 
the vital SLS-deficient ΔsagA strain (1 x 107 cfu,), which is isogenic to the M49 wildtype and 
heat-inactivated preparations of the M49 wildtype (8 x 107 cfu, four injections once a week, 
n=6). Control mice were administered equivalent volumes of solvent alone (saline, n=6) or left 
without treatment (tumor, n=6). Animals were sacrificed at day 28 or when they became 
moribund before the tumor volume reached 2000 mm³. Tumor growth was only at later stages 
affected and when comparing with our previous studies on using vital as well as lysed wild 
type bacteria, to a lesser extend (graphical presentation adopted from Linnebacher et al., 2008 
and Maletzki et al., 2008). *p<0.05 vs. saline, **p<0.001 vs. saline U-Test. 
3.4 Gross findings & hematological alterations post ∆sagA infection 
To further validate the potential of SLS to influence tumor growth, we analyzed systemic 
parameters of animals treated with ΔsagA in more detail. Analysis of blood samples from 
ΔsagA infected animals revealed no alteration regarding the number of circulating 
leukocytes. However, thrombocyte as well as hematocrit levels were found to be decreased 
post infection (Figure 4a). Similarly, activities of the plasma enzymes ASAT and LDH were 
reduced, while levels of ALAT were not affected by bacteria (Figure 4b). In this case, the 
infection-mediated decrease in blood LDH activities might correlate with the retardation of 
tumor growth observed in vivo. 
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As these data indicated an inflammatory reaction in the ΔsagA treated animals, we 
subsequently determined plasma cytokine levels from infected and non-infected animals 
(Figure 4c). Analysis of the neutrophile chemotaxis polypeptide G-CSF and the GM-CSF 
showed slight increases post infection which were, however not statistically significant. 
Levels of both cytokines displayed 2-fold rises post infection (p=0.256 vs. saline (G-CSF) and 
p= 0.007 vs. saline (GM-CSF), t-test). A similar pattern was seen for IL6 (p=0.62), while the 
Th1 cytokines TNF-α and IFN-γ showed no alterations at all. 
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Fig. 4. Assessment of systemic blood parameters. (A) Numbers of leukocytes, 
thrombocytes, and hematocrit levels as well as (B) plasma enzyme activities of ALAT, ASAT 
and LDH from ΔsagA-infected and control animals at day 28. (C) Levels of Th1 and Th2 
cytokines in serum of treated and untreated mice. Mice received a single i.t. infection of the 
ΔsagA strain (1x 107 cfu). Control animals received equivalent volumes of PBS (saline) or no 
injection (tumor). Values are given as the mean±SEM. U-Test. 
A 
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3.5 Flow cytometric phenotyping of circulating leukocytes 
Next, flow cytometric phenotyping of circulating leukocytes was performed. As shown in 
Table 1, we observed higher numbers of circulating NK cells in animals treated with the 
ΔsagA strain (34.6 ± 7.1% vs. saline 16.5 ± 2.7%). Similarly, levels of Gr1+ granulocytes were 
also raised (32.5 ± 4.6% vs. saline 25.0 ± 3.0%). Regarding the number of T cells, no 
significant differences were obtained between the infection and control groups. Likewise, 
numbers of circulating CD19+ pre B cells showed no alteration after therapy with values 
remaining similar to controls. Thus, in our experimental system, microbial therapy with 
SLS-deficient or heat-inactivated S. pyogenes preparations seemed to affect exclusively the 
innate arm of the immune system. 
 Control Tumor Saline ΔsagA 
CD3+CD4+ 19.5 ± 1.9 15.7 ± 1.4 8.6 ± 1.4 14.1 ± 0.9 
CD3+CD8+ 10.9 ± 0.7 9.5 ± 1.3 6.9 ± 1.7 10.3 ± 0.5 
CD19+ 56.5 ± 1.9 42.2 ± 4.1 31.4 ± 2.5 41.6 ± 4.2 
NK1.1+ 14.8 ± 2.6 15.8 ± 1.8 16.5 ± 2.7 34.6 ± 7.1 
Gr1+ 9.5 ± 2.4 19.8 ± 3.1 25.0 ± 3.0 32.5 ± 4.6 
Values are given as mean ± SEM. ΔsagA-infected animals (n=7); saline-treated animals (n=6); tumor 
control animals (n=7); U-Test. 
Table 1. Flow cytometric phenotyping of whole blood in control groups (control, tumor, 
saline) and post infection with the ΔsagA strain (% positive cells). 
3.6 Analysis of antitumoral immune responses  
Despite raised levels of infiltrating granulocytes, especially in the boundary areas of treated 
tumors (Figure 5a), we did not observe any significant difference in the number of CD4+ and 
CD8+ lymphocytes infiltrating tumors between control and treatment groups (data not 
shown).  
In a first series of experiments, reactivity against syngeneic tumor cell lines was tested in 
ELISpot assays using lymph node derived lymphocytes as effector cells from control as well 
as ΔsagA-treated animals. Surprisingly, recognition of tumor cells was restricted to the 
syngeneic colorectal carcinoma cell line CMT-93. Other tested cells (i.e. Panc02, EL4) did not 
induce release of IFN-γ from lymphocytes of ΔsagA treated animals (Figure 5b).  
In a more functional cytotoxicity assay, splenocytes were used as effectors. Again, Panc02 
tumor cells were only ineffectively lysed by immune cells from infected mice (22.1 ± 2.5 % 
vs. saline 6.7 ± 1.7 %). Similar results were obtained with the non-cancerous MC3T3-E1 
fibroblasts and with PBMCs (Figure 5c), indicating only little specific killing activity of 
effector cells. In contrast, we again observed most lytic activity against the syngeneic tumor 
cell line CMT-93 (35.8 ± 12.7 % vs. saline: 22.2% ± 7.5 %) and additionally against EL4 (38.6 ± 
11.4 % vs. saline: 18.2% ± 3.0 %).  
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Fig. 5. Data of immune responses from Panc02 tumor-carrying mice. (A) Quantitative 
analysis of tumor-infiltrating As-D chloroacetate esterase-positive leukocytes shown as 
number of positive cells per mm2. Leukocytes were found especially in boundary areas, and 
minor in the center of treated tumors. (B) Quantitative analysis of IFN-γ ELISpot assay. 
Reactivity of splenocytes against tumor targets was tested after co-incubation overnight at 
an E:T cell ratio of 30:1. Splenocytes from infected animals at 28 days after i.t. bacterial 
infection showed a marginally higher reactivity against target cells than those from control 
animals. (C) Quantitative analysis of cytotoxicity using LDH release assay. Lymphocytes 
were isolated from mesenteric lymph nodes and co-cultured with targets for 24 h at an E:T 
ratio of 30:1. Lymphocytes from infected animals at 28 days after i.t. bacterial infection lysed 
syngeneic tumor cell lines EL4 and CMT-93, but only to a minor extend Panc02 cells. 
Experiments were performed in triplicates. Values are given as the mean±SEM. *p<0.05 vs. 
saline, U-Test. 
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4. Discussion 
Different observations indicate that exposure by vaccination or infection to pathogen-
associated molecular patterns (PAMP) can have beneficial effects on neoplastic diseases 
(Hobohm et al., 2008). PAMP recognizing TLRs serve as a first line of defense for the immune 
system, inducing soluble and cellular mediators of innate immunity and initiating key steps of 
the adaptive immune response. In recent years, manipulating the immune response via TLR 
stimulation has gained therapeutic and/or prophylactic value for cancer. In particular, 
administration of the synthetic TLR9 agonist CpG-ODN is being developed for cancer vaccines 
and cancer therapy, due to its described capacity to stimulate Th1-like innate and adaptive 
anti-tumor responses in numerous preclinical models (Krieg 2007; Jacobs et al., 2010). Another 
potent inducer of tumor-directed cellular immune responses is the TLR7 agonist imiquimod. 
In recent years, several studies proved enhancement of antigen-specific T cell activation 
followed by tumor eradication (Rechtsteiner et al., 2005; Prins et al., 2006; Xiong & Ohlfest, 
2011). Very recently, we provided evidence for tumor growth control by avitalized gram-
positive bacteria. In these experiments, therapeutic application of avitalized bacteria effectively 
delayed tumor growth accompanied by increased numbers of tumor-infiltrating immune cells 
mainly belonging to the innate arm of the immune system (Klier et al., 2011).  
In line with this, we previously observed that treatment with S. pyogenes leads to pancreatic 
tumor reduction or even cure by the orchestrated induction of innate and subsequent 
adaptive antitumoral immune responses (Linnebacher et al., 2008; Maletzki et al., 2008).  
However, little is known about the nature of active components responsible for this success. 
We hypothesized, that bacterial toxins are the most obvious candidate molecules to explain 
the antitumoral activity of S. pyogenes. Here, we explored the potential of the streptococcal-
elaborated oxygen-stable cytolysin Streptolysin S. In agreement with previous data referring 
to the broad cytolytic spectrum of SLS, we were able to confirm that it also efficiently kills 
tumor cells and in particular Panc02 mouse pancreatic carcinoma cells. To a minor part, 
these effects could be attributed to the induction of caspase-dependent apoptosis. In a first 
series of in vivo experiments, the SLS-deficient mutant S. pyogenes strain ΔsagA showed only 
impaired antitumoral activity. This strain has been described to exhibit strongly reduced 
epithelial cell killing compared with SLS-producing wildtype strains (Datta et al., 2005; Lin 
et al. 2009). Moreover, minimal evidence of necrosis and tissue injury is seen post infection 
with SLS-negative bacteria in murine models of skin lesions (Datta et al., 2005).  Similarly, 
local infection with the ΔsagA strain exhibited antitumoral potential only at later time-
points post infection in our syngeneic murine Panc02 tumor model. This therapeutic success 
was significantly weaker than what we observed in our earlier studies using vital as well as 
lysed preparations of S. pyogenes. The hypothesis that SLS is a major antitumoral-acting 
molecule could be further substantiated in a second series of in vivo experiments. The 
application of streptococci depleted of active SLS by heating also resulted only in reduced 
antitumoral activity even after repetitive local treatments.  
However, despite incomplete eradication of tumors, we want to strengthen the fact, that 
both preparations led to therapeutic responses as detected by significant reduction in tumor 
volumes. Thus, other factors are likely to contribute to the antitumoral effects of living and 
lysed S. pyogenes (e.g. M-Protein, superantigens, lipoteichoic acid) (Chau et al., 2009). 
Moreover, these findings hint towards a significant contribution of the immune system in 
partial control of tumor growth. 
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To understand the underlying immunological effects evoked by an inflammatory reaction in 
the ΔsagA treated animals, leading to reduced but not completely abolished antitumoral 
potential, ex vivo analyses were performed. Our observations imply an ongoing 
inflammatory response including systemic production of Th1 cytokines such as G-CSF and 
GM-CSF as well as raised levels of circulating NK cells and granulocytes. Functional 
analyses revealed recognition of syngeneic tumor cells as detected by IFN-γ release from 
lymphocytes obtained from infected animals. However, these effects were rather supposed 
to be mediated by activated NK cells than by tumor antigen specific T cells. This finding is 
additionally supported by the lymphocytes’ killing activity especially towards the syngeneic 
tumor cell lines EL4 and CMT-93, but only marginally towards Panc02 cells.  
To explain our findings, we propose that intratumoral injection of SLS-deficient 
streptococcal preparations leads to minor tumor cell damage driven by cytotoxic activity of 
other bacterial components. This triggers a comparably weak local inflammatory reaction 
followed by negligible systemic activation of the immune system. Thus, few specific 
antitumoral effector cells will be activated which can not totally control tumor growth 
whereas NK cells are the main effector type population mediating some degree of tumor 
growth control. The question, whether SLS may be an interesting molecule for tumor 
therapy will be addressed in ongoing trials. 
5. Conclusion 
Based on our previous findings on Streptococcus pyogenes-mediated eradication of 
established pancreatic murine tumors, we here elucidated the impact of the cytolytic toxin 
Streptolysin S on tumors in vitro and in vivo. We were able to show that direct exposure of 
the toxin to tumor cells results in a dose-dependent increase in cell damage. Contrary, the 
SLS-deficient ΔsagA strain showed only minor cytolytic potential. In vivo, a single i.t. 
injection of the ΔsagA strain affected pancreatic carcinomas only at later time points. This 
hints towards –at least partial- growth control of tumors by SLS, since comparable effects 
were observed following repetitive local applications of SLS-inactivated (by heating) 
bacteria. This finding is further supported by the histologic observation of ΔsagA-infected 
tumors. Those tumors showed slight increases in infiltrating granulocytes. Moreover, we 
found that recognition and killing of tumor cells was not restricted to Panc02 cells, but also 
detectable towards other syngeneic tumor entities. Taken together, we here provide clear 
evidence of strong antitumoral effects of SLS. However, in terms of the delayed, but 
significant impact on tumor growth in vivo, other factors are likely to contribute to the 
strong antitumoral effects of wildtype S. pyogenes. 
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